Memantine Accord (Memantine Hydrochloride)

Memantine Hydrochloride works as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium influx caused by prolonged glutamate activation, it limits neuronal injury while allowing normal synaptic signaling that supports memory and learning.

The dosing regimen is individualized and set by the prescribing healthcare professional. Typically, therapy starts with a low dose that is gradually increased, but the exact schedule should follow local prescribing information and the clinician’s judgment.

Safety data for Memantine during pregnancy and lactation are limited, and the product is classified with an unknown pregnancy category. Use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the Memantine Accord product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas drugs such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with an inhibitor for broader symptomatic coverage.

Store Memantine Accord at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Memantine Accord is taken orally as a tablet. Swallow the tablet whole with water; it may be taken with or without food. Follow the dosing schedule prescribed by the treating clinician.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, seizures or an increase in seizure frequency, hepatic dysfunction, and emergent suicidal thoughts or mood changes. Prompt medical attention is required if any of these occur.

Memantine should be avoided in patients with known hypersensitivity to memantine or any excipients, in those with uncontrolled severe renal impairment without dose adjustment, and in individuals where the risk‑benefit ratio is unfavorable, such as certain pregnant or breastfeeding patients.